A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine from Lower-Valent Pneumococcal Conjugate Vaccines in the French Pediatric Population.

ABSTRACT:

Introduction

The pneumococcal conjugate vaccine (PCV) with valency of 20 (PCV20) was approved for pediatric use by the European Commission in 2024. However, PCV20 is not yet implemented into the French infant National Immunization Program (NIP). In this cost-effectiveness analysis, we compared PCV20 under a 3 + 1 schedule to the current standard of care (13-valent PCV [PCV13]) or 15-valent PCV (PCV15), both under a 2 + 1 schedule, for infant vaccination in France.

Methods

The study adopted a multiple-cohort population-level model under the French Collective perspective over a 10-year time horizon. Inputs were sourced from published and unpublished studies conducted in the French population, where available. Clinical outcomes included disease cases (i.e., invasive pneumococca

SUBMITTER: Fievez S 

PROVIDER: S-EPMC12425875 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature